Longembolie met intermediair-hoog risico op overlijden

• Patients with intermediate-high risk pulmonary embolism have a different mix of clinical symptoms.
• Optimal treatment of patients with intermediate high-risk pulmonary embolism is necessary to prevent short-term mortality.
• According to the current guidelines, the use of standard coagulation is the treatment of choice in hemodynamic stable patients with intermediate-high risk pulmonary embolism.
• Systemic thrombolytic therapy is recommended in patients with intermediate-high risk pulmonary embolism who circulatory deteriorate or who did not respond appropriately to standard anticoagulation.
• Catheter-guided thrombolysis is reserved for patients with intermediate-high risk pulmonary embolism who have a contraindication for systemic thrombolysis or did not respond to systemic thrombolysis.
• The timing and choice for the right treatment are significant treatment dilemmas.
• The development of pulmonary embolism response teams helps in the decision-making in patients with intermediate high-risk pulmonary embolism.

Conflict of interest and financial support: none declared.